345 related articles for article (PubMed ID: 8077361)
1. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
2. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
[TBL] [Abstract][Full Text] [Related]
3. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.
Delmas PD; Gineyts E; Bertholin A; Garnero P; Marchand F
J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992
[TBL] [Abstract][Full Text] [Related]
4. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
6. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
[TBL] [Abstract][Full Text] [Related]
7. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
8. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
9. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
Garnero P; Delmas PD
J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.
Uebelhart D; Gineyts E; Chapuy MC; Delmas PD
Bone Miner; 1990 Jan; 8(1):87-96. PubMed ID: 2106358
[TBL] [Abstract][Full Text] [Related]
12. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.
Bonde M; Qvist P; Fledelius C; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1995 Mar; 80(3):864-8. PubMed ID: 7883844
[TBL] [Abstract][Full Text] [Related]
13. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.
Body JJ; Delmas PD
J Clin Endocrinol Metab; 1992 Mar; 74(3):471-5. PubMed ID: 1740478
[TBL] [Abstract][Full Text] [Related]
14. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
[TBL] [Abstract][Full Text] [Related]
15. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
16. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
17. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
18. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.
Fledelius C; Kolding I; Qvist P; Bonde M; Hassager C; Reginster JY; Hejgaard J; Frøokiaer H; Christiansen C
Scand J Clin Lab Invest; 1997 Feb; 57(1):73-83. PubMed ID: 9127460
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
20. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]